Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of JP-1366 with NSAIDs and Ethnic Comparison
NCT05181124Phase 1Completed
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zastaprazan in gastroesophageal reflux disease (GERD), gastric ulcer and peptic ulcer disease (PUD) (4 arms), sponsored by Onconic Therapeutics Inc. Primary endpoints: Pharmacokinetics of Aceclofenac, Pharmacokinetics of JP-1366 at Day 9 and 3 more. Started Mar 2021; status: completed.
02
Drugs
zastaprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcerpeptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT05181124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181124.